Investment

The spinout has revealed it added approximately $6m to a series A round backed by University of Pennsylvania and IP Group last year, bringing its total size to about $59m.

Royal Vopak, Mitsubishi and Covestro helped the Erlangen–Nuremberg hydrogen storage technology spinout collect $19m in funding.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Mission Bay Capital has backed a series B round for orphan diseases drug developer Glycomine, which also attracted Novo, Asahi Kasei Pharma and Chiesi.

BlueDot, a disease containment technology spinout set up by St Michael’s Hospital and Mars Innovation, has secured series A capital.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

With hundreds of university venture funds, internal commercialisation vehicles and third-party firms the reality in today’s innovation ecosystem, selecting the nominees and the winner for Investment Unit of the Year is increasingly challenging.

Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.

Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.

Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.